Substitute for form 1449A&B/PTO	**Complete if Known**	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/561,304
	Filing Date	December 19, 2005
	First Named Inventor	Del Borgo, Mark
	Art Unit	1654
(Use as many sheets as necessary)	Examiner Name	Ronald T. Niebauer
Sheet 1 of 1	Attorney Docket Number	087521-000000US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number — Number Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document — Country Code[3]	Number[4]	Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	AB	EP	0251615	A	01/07/1988	Genentech, Inc.		☐
	AC	WO	03/030930	A	04/17/2003	Howard Florey Institutue		☐
	AD							☐
	AE							☐
	AF							☐

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	BA	M.P. DEL BORGO et al.; Analogs of insulin-like Peptide 3 (INSL3) B-chain are LGR8 Antagonists in Vitro and in Vivo; Journal of Biological Chemistry; May, 2006; pp 13068-13074; Vol. 28; No. 19.	☐

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

61302723 v1